Document Detail


Decision models for assessing the cost effectiveness of drug-eluting stents.
MedLine Citation:
PMID:  15952924     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Percutaneous coronary intervention is an increasingly common treatment for many people with coronary disease. Randomised trials using antiproliferative, drug-eluting stents (DES) have shown important reductions in the need for repeat procedures after initial percutaneous coronary intervention. These trials indicate that the growing use of DES has the potential to create major clinical benefits for patients; however, in actual practice, the associated costs may cause financial crises for hospital systems. This paper reviews previously published DES economic decision models from both societal and hospital perspectives. From a social perspective, additional spending for new technologies may be acceptable if these technologies convincingly improve the lives of patients. The models reviewed suggest that DES incurs large costs to both society and hospitals, and currently offers uncertain clinical benefits. More research is recommended to identify high-risk patients who stand to gain significant health benefits from this therapy.
Authors:
David F Kong; Eric L Eisenstein
Related Documents :
10881974 - Deinstitutionalisation for long-term mental illness: cost differences in hospital and c...
20363094 - Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intra...
11794914 - Diabetes in pregnancy: efficacy and cost of hospitalization as compared with ambulatory...
23996824 - Acquiring credentials in bedside ultrasound: a cross-sectional survey.
7301524 - The team fights the scourge of poliomyelitis.
12467814 - Multivariate analysis of risk factors for hospital mortality in valvular reoperations f...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  6     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-06-14     Completed Date:  2006-04-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  965-74     Citation Subset:  IM    
Affiliation:
Duke University Medical Centre, Duke Clinical Research Institute, DUMC Box 3850, Durham, NC 27710, USA. kong0008@dcri.duke.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary / economics
Coronary Restenosis / economics,  prevention & control
Cost-Benefit Analysis
Decision Support Techniques*
Drug Delivery Systems / economics,  methods
Growth Inhibitors / administration & dosage,  economics*
Humans
Stents / economics*
Chemical
Reg. No./Substance:
0/Growth Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Use of medications in Wolff-Parkinson-White syndrome.
Next Document:  Pharmacological strategies for trichotillomania.